Monoclonal antibody effective therapy for diabetic retinopathy

October 7, 2012
Monoclonal antibody effective therapy for diabetic retinopathy
An antibody can reduce retinal vascular leakage and inflammation in rat models of diabetic retinopathy, according to a study published online Oct. 1 in Diabetes.

(HealthDay)—An antibody can reduce retinal vascular leakage and inflammation in rat models of diabetic retinopathy, according to a study published online Oct. 1 in Diabetes.

Kyungwon Lee, from the University of Oklahoma Health Sciences Center in Oklahoma City, and colleagues investigated the effect of a monoclonal antibody targeting the E1E2 domain of Wnt coreceptor low-density lipoprotein receptor-related protein 6 (Mab2F1) on in vitro and in vivo.

The researchers found that Mab2F1 inhibited Wnt signaling in epithelial cells. Mab2F1 also reduced the levels of β-catenin as well as angiogenic and inflammatory factors induced by high-glucose medium in retinal endothelial cells. In rat models of ischemia-induced retinopathy and streptozotocin-induced diabetes, Mab2F1 significantly reduced retinal vascular leakage.

"In conclusion, Mab2F1 inhibits canonical Wnt signaling, vascular leakage, and inflammation in the retina of diabetic retinopathy models, suggesting its potential to be used as a therapeutic agent in combination with other antiangiogenic compounds," Lee and colleagues write.

Explore further: Apolipoproteins are biomarkers for diabetic retinopathy

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Apolipoproteins are biomarkers for diabetic retinopathy

June 29, 2012
(HealthDay) -- In patients with diabetes, with or without diabetic retinopathy, serum apolipoproteins (apos) are associated with markers of systemic and retinal microvascular dysfunction, according to a study published in ...

Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases

July 27, 2012
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because ...

Low HDL cholesterol ups risk of diabetic nephropathy

August 22, 2012
(HealthDay) -- High-density lipoprotein cholesterol (HDL-C) is an independent risk factor for the development of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes, according to research published ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.